Akari Therapeutics (AKTX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear

Akari Therapeutics

NASDAQ: AKTX · Real-Time Price · USD
0.92
-0.01 (-1.47%)
At close: Oct 03, 2025, 3:59 PM
0.90
-1.75%
After-hours: Oct 03, 2025, 06:52 PM EDT

Akari Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 26K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a n/a 1K n/a n/a 13K n/a n/a n/a 1K n/a n/a 942.00 1.01K 1.01K 1.03K 1.05K 1.03K
Gross Profit
n/a n/a 13K n/a n/a -13K n/a n/a n/a -1K n/a n/a -942 -1.01K -1.01K -1.03K -1.05K n/a
Operating Income
-3.12M -3.52M -5.28M -2.93M -7.45M -5.99M -3.8M -3.8M -9.21M -4.59M -6.01M -6.01M -5.82M -5.24M -5.87M -1.46M -4.33M -5.55M
Interest Income
n/a n/a 1K 3K 2K 2K 11.45 n/a 59.06K 30K 18.81 18.81 3.96K 4.36K 3.98K 1.37K 1.51K 3.73K
Pretax Income
-1.9M -3.71M -3.77M -2.9M -7.56M -5.57M -3.5M -3.5M -3M 1M -3.45M -3.45M -5.68M -5.18M -5.79M -1.45M -4.35M -5.84M
Net Income
-1.9M -3.71M -3.77M -2.9M -7.56M -5.57M -3.5M -3.5M -3M 1M -3.45M -3.45M -5.54M -5.11M -5.61M -1.43M -4.38M -5.84M
Selling & General & Admin
2.45M 2.71M 3.05M 1.71M 2.24M 3.7M 2.7M 2.7M 5.95M 2.86M 3.73M 3.73M 2.97M 3.1M 2.02M 1.89M 2.15M 2.02M
Research & Development
667K 813K 1.25M 143K 3.31M 2.28M 4.44M 4.44M 3.25M 1.73M 3.44M 3.44M 2.85M 2.14M 3.85M -430.16K 2.18M 3.53M
Other Expenses
n/a n/a 983K 1.07M n/a -2 n/a n/a -22.81K -11 n/a n/a -9.21K -7.11K -11.12K -3.55K -5.09K n/a
Operating Expenses
3.12M 3.52M 5.28M 2.93M 5.55M 5.98M 3.52M 3.52M 9.21M 4.59M 3.46M 3.46M 5.82M 5.24M 5.87M 1.46M 4.33M 5.55M
Interest Expense
50K 55K 124K 69K 51K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a 3.69M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
3.12M 3.52M 5.28M 2.93M 7.45M 5.99M 3.52M 3.52M 9.21M 4.59M 3.46M 3.46M 5.82M 5.24M 5.87M 1.46M 4.33M 5.55M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a -0.00 -0.00 n/a n/a -136.17K -67.59K -175.19K -26.27K 29.09K n/a
Shares Outstanding (Basic)
15.73K 272.00 11.94K 12.19K 9.42K 6.73K 5.39K 5.06K 5.06K 3.74K 3.42K 3.42K 2.97K 2.68K 2.41K 2.32K 1.92K 1.92K
Shares Outstanding (Diluted)
15.73K 272.00 11.94K 12.19K 9.42K 6.73K 5.39K 5.06K 5.06K 3.79K 3.42K 3.42K 2.97K 2.68K 2.41K 2.32K 1.92K 1.92K
EPS (Basic)
-60.2 -13.58K -40 -240 -80 -80 -60 -60 -60 20.00 -100 -100 -180 -200 -240 -60 -220 -300
EPS (Diluted)
-121.8 -13.58K -40 -240 -80 -80 -60 -60 -60 20.00 -100 -100 -180 -200 -240 -60 -220 -300
EBITDA
-1.84M -3.65M -3.65M -4.51M -7.51M -5.98M -3.8M -3.8M -4M -4.59M -6.01M -6.01M -5.82M -5.24M -5.87M -1.46M -4.33M -5.55M
EBIT
-1.84M -3.65M -3.65M -2.83M -7.51M -5.99M -3.8M -3.8M -4M -4.59M -6.01M -6.01M -5.82M -5.24M -5.87M -1.46M -4.33M -5.55M
Depreciation & Amortization
n/a n/a 1K -1.56M -58K 13K 1.07K 1.07K 1.85K 1K 1.03K 1.03K 942.00 1.01K 1.01K 1.03K 1.05K 1.03K